Luciferase Stable Cell Line - Raji

Therapies rooted in immuno-oncology (IO), including checkpoint inhibitors, bispecific antibodies, and CAR-T-cell therapies, have demonstrated notable efficacy in treating various cancer types. Researchers utilized the Luciferase Stable Cell Line - Raji to investigate immuno-oncology (IO)-based therapies, aiming to address adverse events like cytokine release syndrome (CRS). By employing an in vivo PBMC humanized mouse model, treatment efficacy against specific tumors and concurrent cytokine release profiles post-CD19xCD3 bispecific T-cell engager (BiTE) treatment were assessed. Results demonstrated predictive efficacy for tumor control and stimulated cytokine release, capturing donor variability. The PBMC-engrafted model proves sensitive and reproducible, aiding in identifying patient-specific treatment efficacy and complication development in immuno-oncology therapies.

Figure 1. Researchers assessed cytokine release in humanized NSG-variant mice with Raji-Luc tumors after various immune-oncology treatments. Luciferase Stable Cell Line - Raji served to monitor tumor burden in mice through IVIS imaging, revealing treatment efficacy. The Raji_Luc cell line, acquired from Creative Biogene, is a single-cell line expressing Firefly luciferase with an emission peak wavelength of 550 nm. (Yang, J., et al., 2023)